A Comparison of Three Extrusion Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Comparison of Three Extrusion Systems
The authors conducted an experiment to determine the type of extrusion that provides the best productivity and pellet quality. This article contains online bonus material.


Pharmaceutical Technology
Volume 35, Issue 1

16. D. Sonaglio et al., Pharmazie 52 (2), 129–134 (1997).

17. D. Djuric et al., Eur. J. Pharm. Biopharm. 71 (1), 155–160 (2009).

18. A. Debunne, C. Vervaet, and J.P. Remon, Eur. J. Pharm. Biopharm. 54 (3), 343–348 (2002).

19. A. Dukić et al., Eur. J. Pharm. Biopharm. 66 (1), 83–94 (2007).

20. H. Kanbe et al., Int. J. Pharm. 337 (1–2), 56–62 (2007).

21. A. Dukić-Ott et al., Eur. J. Pharm. Biopharm. 70 (1), 302–312 (2008).

22. K.E. Fielden, J.M. Newton, and R.C. Rowe, Int. J. Pharm. 97 (1–3), 79–92 (1993).

23. E. Jerwanska et al., Int. J. Pharm. 121 (1), 65–71 (1995).

24. J.J. Sousa et al., Int. J. Pharm. 144 (2), 159–169 (1996).

25. L. Hellén et al., J. Pharm. Tech. Int. 4 (9), 50–60 (1992).

26. G.A. Hileman et al., Int. J. Pharm. 100 (1–3), 71–79 (1993).

27. C.C. Ku et al., Drug Dev. Ind. Pharm. 19 (13), 1505–1519 (1993).

28. B. Bataille, K. Ligarski, and M. Jacob, Pharm. Acta Helv. 65 (12), 334–337 (1990).

29. D. Sonaglio et al., Int. J. Pharm. 115 (1), 53–60 (1995).

30. K.A. Mehta et al., J. Control. Release 63 (1–2), 201–211 (2000).

31. S. Galland et al., Chem. Eng. Res. Des. 81 (9), 1237–1242 (2003).

32. S. Galland et al., Powder Technol. 157 (1–3), 156–162 (2005).

33. P. Kleinebudde and H. Lindner, Int. J. Pharm. 94 (1–3), 49–58 (1993).

34. D. Lutchman, C.M. Dangor, and D. Perumal, J. Microencapsul. 22 (6), 643–659 (2005).

35. C. Vervaet et al., Int. J. Pharm. 107 (1), 29–39 (1994).

36. C. Vervaet and J.P. Remon, Int. J. Pharm. 133 (1–2), 29–37 (1996).

37. R. Dietrich and R. Brausse, Pharm. Ind. 50 (10), 1179–1186 (1988).

38. A.M. Juppo et al., Eur. J. Pharm. Biopharm. 44 (2) 205–214 (1997).

39. P.J. Harrison, J.M. Newton, and R.C. Rowe, J. Pharm. Pharmacol. 37 (10), 686–691 (1985).

40. J.F. Pinto, G. Buckton, and J.M. Newton, Int. J. Pharm. 83 (1–3), 187–196 (1992).

41. L. Baert and G.R.B. Down, Int. J. Pharm. 107 (3), 219–222 (1994).

42. C. Lustig-Gustafsson et al., Eur. J. Pharm. Sci. 8 (2), 147–152 (1999).

43. G. Tomer, F.Podczeck, and J.M. Newton, Int. J. Pharm. 217 (1–2), 237–248 (2001).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here